Archives
-
From CCR7–Notch1 Biology to Translational Rigor
2026-10-06
A source-grounded perspective on CCR7–Notch1 stemness biology and how heparin-affinity purification can support more reproducible translational research without overstating the evidence.
-
HyperScribe T7 RNA Synthesis Kit Overview
2026-10-06
The HyperScribe™ T7 High Yield RNA Synthesis Kit (SKU K1047) is a research-use-only in vitro transcription kit supplied by APExBIO. Its stated scope includes T7 RNA polymerase transcription and the preparation of several RNA formats, but no matched paper evidence is available to independently verify performance or application-specific outcomes.
-
Candida EVs, Nrg1, and Hyphal Suppression
2026-10-05
A 2026 study reports that accumulated Candida albicans extracellular vesicles suppress hyphal development by increasing the transcriptional repressor NRG1 through an SKO1- and BRG1-associated regulatory pathway. Evidence from transcriptomics, clinical isolates, genetic comparisons, and a mouse candidemia model connects this mechanism to reduced fungal burden, while important questions remain about EV cargo identity and applicability to human disease.
-
Hypoxia, Immunometabolism, and the Tumor Microenvironment
2026-10-05
This 2025 Cancer Letters review presents hypoxia and immune metabolism as interacting forces that shape tumor progression and immunosuppression, rather than as isolated features of the tumor microenvironment. Its main contribution is an integrated mechanistic framework linking oxygen limitation, metabolic competition, HIF signaling, immune-cell dysfunction, and therapeutic opportunity while emphasizing that most proposed interventions still require context-specific validation.
-
DiscoveryProbe Metabolism-related Compound Library
2026-10-04
The DiscoveryProbe™ Metabolism-related Compound Library is an APExBIO collection of 493 metabolism-focused small molecules. No matched paper evidence was provided, so its documented scope is limited to the supplier’s product description and does not establish biological performance or experimental outcomes.
-
Tubastatin A in Post-Resuscitation Myocardial Injury
2026-10-03
A porcine cardiac-arrest study links Tubastatin A treatment with less post-resuscitation myocardial dysfunction, lower cardiac injury biomarkers, and reduced markers associated with GSDME-mediated pyroptosis and MLKL-mediated necroptosis. The findings extend HDAC6 inhibitor research into a clinically relevant large-animal model, while remaining exploratory because the study does not establish direct HDAC6 dependence or causality between pathway markers and cardiac protection.
-
Fucoidan and Irinotecan-Induced Steatohepatitis
2026-10-02
A 2026 International Immunopharmacology study identifies a gut–liver axis mechanism in irinotecan-induced steatohepatitis: intestinal barrier failure permits LPS translocation, which promotes hepatic neutrophil extracellular trap accumulation. In mice, Fucoidan improved barrier-associated responses, partially corrected microbiota disruption, reduced LPS movement and NET accumulation, and offers a mechanistic framework for studying chemotherapy-associated liver injury.
-
4-Hydroxytamoxifen Protocol and QC Guide
2026-10-01
4-Hydroxytamoxifen (SKU B6167) provides a DMSO-compatible estrogen receptor modulator for controlled receptor, cancer-cell, apoptosis, and cardiac myocyte workflows. It should not be selected for protocols requiring aqueous or ethanol solubility, and solution stability should not be assumed during long-term storage.
-
Omeprazole A2845: Practical Research Protocol
2026-10-01
Omeprazole (SKU A2845) provides a research-grade H+,K+-ATPase inhibitor for controlled gastric acid secretion research, antiulcer activity studies, and related preclinical assay workflows. This guide addresses solubility, storage, controls, and interpretation; it is not a clinical, diagnostic, or dosing guide and does not substitute for matched paper evidence.
-
GS967 and the Late Sodium Current in Cardiac Aging
2026-09-30
Late sodium current is emerging as a mechanistic bridge between electrical instability, calcium overload, delayed relaxation, and age-associated cardiac dysfunction. This article examines how GS967 can help translational researchers connect ventricular myocyte electrophysiology with tissue-level arrhythmia phenotypes, while outlining assay design, competitive positioning, and the limits of preclinical interpretation.
-
Lipid Nanoparticles in Cancer Immunotherapy
2026-09-30
This 2025 review explains how lipid nanoparticles can address degradation, cellular uptake, biodistribution, and toxicity barriers in nucleic acid cancer immunotherapy. Its main contribution is an integrated framework connecting cargo selection, nanoparticle properties, immune-cell delivery, and translational limitations rather than introducing a new formulation.
-
2-Deoxy-D-Glucose and T-Cell Immunometabolism in OLP
2026-09-29
The reference study shows that oral lichen planus-derived T cells exhibit elevated glycolytic and mTOR-associated activity, and that 2-deoxy-D-glucose reduces their proliferation and ability to trigger keratinocyte apoptosis. Rapamycin strengthened these effects, supporting a mechanistic connection between glycolytic metabolism, mTOR signaling, T-cell survival, and epithelial injury.
-
RGFP966: HDAC3 Inhibition Meets HO-1 Assays
2026-09-29
RGFP966 is a selective HDAC3 inhibitor that can help dissect how chromatin regulation influences cellular stress responses. This article presents a practical, activity-centered framework for pairing RGFP966 with the live-cell HO-1 probe AMC-Hem while separating established findings from testable experimental hypotheses.
-
CRISPR-Cas Antimicrobial Therapy: Evidence and Limits
2026-09-28
The 2025 review by Yang and colleagues frames CRISPR-Cas as a programmable antimicrobial strategy for selectively eliminating pathogens, removing antibiotic-resistance genes, and engineering bacteriophages. Its main practical contribution is an integrated analysis of CRISPR mechanisms, delivery vehicles, phage applications, and the biological barriers that still separate promising laboratory concepts from deployable therapies.
-
TSA Beyond Tumor Cells: Epigenetics Meets Immunity
2026-09-28
Trichostatin A (TSA) is best understood not simply as a way to alter histone acetylation, but as a context-dependent probe of cell state. This article connects its established cancer-research applications with findings in stressed dendritic cells, then translates those insights into practical experimental choices—while keeping preclinical promise distinct from clinical evidence.